SPONSOR
Ming-Yuan Chen
Total Trials
3
Recruiting
3
Phases
Phase 3
Ming-Yuan Chen is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Oligo-metastatic Cancer, Nasopharyngeal Carcinoma (NPC), Nasopharyngeal Carcinoma.
The trial portfolio spans Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Ming-Yuan Chen
How many clinical trials has Ming-Yuan Chen sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Ming-Yuan Chen, of which 3 are actively recruiting participants. These trials cover conditions including Oligo-metastatic Cancer, Nasopharyngeal Carcinoma (NPC), Nasopharyngeal Carcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Ming-Yuan Chen research focus on?
Ming-Yuan Chen clinical trials span Oligo-metastatic Cancer, Nasopharyngeal Carcinoma (NPC), Nasopharyngeal Carcinoma. The research pipeline includes Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Ming-Yuan Chen clinical trial?
To participate in a Ming-Yuan Chen trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Ming-Yuan Chen trials with current recruitment status updated daily.
Clinical Trials by Ming-Yuan Chen
NCT07481799 Phase 3
Recruiting
Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases
Oligo-metastatic Cancer
NCT07328841 Phase 3
Recruiting
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
Nasopharyngeal Carcinoma (NPC)
NCT06529562
Recruiting
Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma.
Nasopharyngeal Carcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology